"Triptorelin Pamoate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.
| Descriptor ID |
D017329
|
| MeSH Number(s) |
D06.472.699.327.740.320.790 D12.644.400.400.740.320.790 D12.644.456.460.800 D12.644.548.365.740.320.790 D12.776.631.650.405.740.320.790
|
| Concept/Terms |
Decapeptyl- Decapeptyl
- Decapeptyl Trimestral
- Trimestral, Decapeptyl
- Decapeptyl LP
- Decapeptyl Depot
Triptorelin- Triptorelin
- LHRH, Trp(6)-
- GnRH, Trp(6)-
- LHRH, Tryptophyl(6)-
- D-Trp-6-LH-RH
- 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig)
Trelstar- Trelstar
- Triptorelin Embonate
- Embonate, Triptorelin
|
Below are MeSH descriptors whose meaning is more general than "Triptorelin Pamoate".
Below are MeSH descriptors whose meaning is more specific than "Triptorelin Pamoate".
This graph shows the total number of publications written about "Triptorelin Pamoate" by people in this website by year, and whether "Triptorelin Pamoate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triptorelin Pamoate" by people in Profiles.
-
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303.
-
Characterization of multiple pathways modulating aggression in the male clouded leopard (Neofelis nebulosa). Zoo Biol. 2016 Nov; 35(6):474-486.
-
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.
-
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 05 10; 34(14):1584-93.
-
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
-
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100.
-
Sonographic monitoring of ovarian volume during LHRH analogue therapy in women with polycystic ovarian syndrome. J Ultrasound Med. 1988 Apr; 7(4):203-6.
-
Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab. 1985 Jan; 60(1):203-7.